anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) \[with different particle size distribution (PSD) as compared to Treatment A, D, C and E\] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
PURPOSE OF REVIEW: Approximately 30% of syndromic cases diagnosed with CHD, which lure us to further investigate the molecular and clinical challenges behind syndromic CHD (sCHD). The aetiology of sCHD in a majority of cases remains enigmatic due to involvement of multiple factors, namely genetic, epigenetic and environmental modifiable risk factors for the development of the disease. Here, we aim to update the role of genetic contributors including chromosomal abnormalities, copy number variations (CNVs) and single gene mutations in cardiac specific genes, maternal lifestyle conditions, environmental exposures and epigenetic modifiers in causing CHD in different genetic syndromes.
RECENT FINDINGS: The exact aetiology of sCHD is still unknown. With the advancement of next-generation technologies including WGS, WES, transcriptome, proteome and methylome study, numerous novel genes and pathways have been identified. Moreover, our recent knowledge regarding epigenetic and environmental regulation during cardiogenesis is still evolving and may solve some of the mystery behind complex sCHD. Here, we focus to understand how the complex combination of genetic, environmental and epigenetic factors interact to interfere with developmental pathways, culminating into cardiac and extracardiac defects in sCHD.
Extensive burns and full thickness skin wounds can be devastating to patients, even when treated with our current standard of care. There are an estimated 500,000 burns treated in the United States each year. Moreover, in the military environment, soldiers who suffer from extensive burn injuries on the battlefield may benefit from rapid treatments that result in complete closure and protection of the wounds. As such, there is a need for mobile platform technologies that allow fast treatment at the site where the injury occurred, or at the very least at the forward operating sites. This safety investigation of a human amnion membrane powder product for wound healing is a with-in patient-controlled study, enrolling 10 subjects undergoing donor skin graft harvest. The single-center study will include patients undergoing donor skin harvest such that two regions, of at least 25 cm2 and separated by at least a 5 cm gap, of donor site wounds in comparable skin locations, are available for covering with the amnion membrane product and the current institutional standard of care (SOC) covering. The proposed sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.

The primary objective of the study is to evaluate the safety of a human amnion membrane product intended for enhanced wound healing. The secondary objective is efficacy as evidenced by complete wound closure relative to standard of care (SOC) treatment in a similar wound on the same subject at donor sites created for skin grafts at 14 days and 28 days postoperatively.
Based on the assumption that valence is permanently linked to facial responses, we expected that the corrugator muscle is contracted faster in response to overweight persons than to slim persons, whereas we expected faster contractions of the zygomaticus muscle in response to slim persons rather than to overweight persons. To detect such differences, we conducted experiments with different versions of a facial stimulus-response compatibility task that required participants to respond with the two facial muscles to photos of overweight or slim persons. Contrary to the assumption that valence is permanently linked to facial responses, in Experiments 1 and 2, social categories (overweight vs. slim persons) did not influence the response latencies assessed by electromyography. Whereas in Experiments 1 and 2, neutral labels were used for the muscle responses, in Experiment 3, affective response labels (smile vs. frown) were used. In Experiment 3, faster responses with the corrugator to overweight than to slim persons and with the zygomaticus to slim than to overweight persons were obtained. The influence of task and response label is consistent with the theory of event coding that suggests a more flexible link between valence and action.
This panel consisted of 6 health teachers and other school health professionals such as nurses and counselors. They were recruited at each participating school.
The technical problem and the object of the wearing of hydrosoft contact lenses is how to place the latter each day on the eye without care solution toxins so that the eyes remain healthy and the hydrolenses are tolerated in the long term. For this purpose, the spongy hydrolenses must remain absolutely clean and be reliably treated against germs on the surface and in their interior each day in order to counteract the risk of infection. Since care solution toxins deposited on the hydrolens adhere very tenaciously (owing to electrolysis) and are slowly released on to the eye throughout the day and night, it is necessary to design a care method which is free of care solution toxins, which operates with physical forces and contains only substances identical to those in the tear film. A gentle thoroughness gives the hydrolens a particularly long useful life and makes possible the required toxin-free insertion after reliable germ treatment. The lenses are cleaned with a hypertonic surfactant lens cleaner which is not absorbed by the soft lens but itself removes dirt and water from the latter, and are stored in a soft hydrolens storage device which is free of substances foreign to the eye and is more hypertonic than the cleaner to an extent such that it also acts as preservative. Before insertion, the lenses are rinsed with isotonic saline solution which is free of substances foreign to the eye.
The invention relates to producing fine powders of organic medicinal substances and can be used for producing novel pharmaceutical forms. The inventive pharmaceutical composition is produced in the form of multicomponent particles made of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone and a surface active agent. The inventive method for producing the pharmaceutical composition in the form of microcapsulated multicomponent particles made of N-carbamoil-methyl-4-phenyl-2-pyrrolidone involves simultaneously evaporating N-carbamoil-methyl-4-phenyl-2-pyrrolidone and the surface-active agent in a neutral gas medium and co-condensating the thus formed vapours of both components on a deposition surface. During the co-condensation of the two components, the deposition rate vectors of N-carbamoil-methyl-4-phenyl-2-pyrrolidone and the surface-active agent are oriented towards the centre of the deposition surface. The angle between the deposition rate vectors and the angle of inclination of the bisectrix of said angle to the deposition surface are equal to 5-170° and 10-90°, respectively. Microcapsulation is carried out at positive temperatures of the deposition surface either during the co-condensation process or during heating the produced co-condensate up to the positive temperatures when thedeposition surface has negative temperatures.
The invention relates to novel artificial antigen presenting cells (aAPCs).  The aAPC comprises at least one stimulatory ligand and at least one costimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell.  The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an ~off the shelf~ APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
The invention relates to a traditional Chinese medicine (TCM) dispersible tablet and the preparation method thereof, wherein the TCM dispersible tablet contains fine powder or extract of Chinese medicinal materials, water soluble accessories having low melting points, glidants and lubricants. The preparation method thereof comprises the steps of 1). evenly mixing the fine powder or extract fine powder of Chinese medicinal materials with water soluble accessories having low melting points and glidants, adding lubricants into and evenly mixing the mixture for further use; 2) pressing evenly mixed fine power obtained from step 1 into tablets. The TCM dispersible tablet is instantly dispersible, and has a stable quality, and is easy for storing and administration. And, the administration dose is small. The mixture of fine powder or extract fine powder of Chinese medicinal materials with water soluble accessories having low melting points and glidants has excellent flowability, which satisfies the requirement of directly pressing powder into tablets and makes the tablet easy to manufacture.
Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy.
FIELD: biology, experimental medicine, oncology. SUBSTANCE: method involves the use of complex of platinum with coproporphyrin-III as luminescent probe. This probe exhibits the increased selective accumulation in tumor tissue as compared with that in surrounding normal tissues. Coproporphyrin-III can be easily prepared by microbiological procedure. Complex of platinum with coproporphyrin-III is stable at all pH range, well soluble in aqueous solutions and shows higher luminescence quantum yield. EFFECT: improved method of investigation.
INTRODUCTION: Dolutegravir (DTG)-based antiretroviral therapy is the World Health Organization's preferred first-line regimen for all persons with HIV, including pregnant women. While DTG has been implicated as an obesogen associated with greater weight gain compared to other antiretrovirals, there is a paucity of data in pregnant women and their children. The Obesogenic oRigins of maternal and Child metabolic health Involving Dolutegravir (ORCHID) study is investigating associations between DTG, weight gain, and metabolic outcomes in the context of HIV.
MATERIALS & METHODS: ORCHID is a prospective observational study taking place in Cape Town, South Africa (NCT04991402). A total of 1920 pregnant women with and without HIV infection are being followed from ≤18 weeks gestational age to 24 months postpartum with their children. Participants attend eleven study visits: 3 antenatal, delivery, and 7 postnatal visits. Several embedded sub-studies address specific scientific aims. Primary outcome measurements in mothers include anthropometry, blood pressure, body composition, dysglycemia, insulin resistance (IR), and dyslipidemia. Other maternal measures include demographics, resting energy expenditure, viral load, physical activity, dietary intake, hepatic steatosis, and repository specimens. Sub-study measurements include markers of adipose inflammation, gut integrity, and satiety/hunger, subcutaneous adipose tissue morphology and mitochondrial function, and metabolomics. Primary outcome measurements in children include anthropometry, adipose tissue mass, dysglycemia, IR, and dyslipidemia. Other variables include fetal growth, birth outcomes, medical/breastfeeding history, caloric intake, neurodevelopment, and repository specimens. Sub-study measurements include metabolites/lipid subspecies in umbilical cord blood, as well as breast milk composition and DTG exposure.
DISCUSSION: ORCHID will play a pivotal role in defining obesogenic mechanisms and clinical consequences of DTG use in pregnancy in women with HIV and their children. It will provide insights into metabolic disease risk reduction in the context of HIV/DTG, identify intervention targets, and inform public health approaches to diminish chronic metabolic co-morbidities for women and children.
BACKGROUND: Most people diagnosed with chronic hepatitis B (CHB) need treatment to help reduce the risk of liver disease and limit disease transmission. Therapeutic vaccine (TV) candidates have been under study for their clinical effects on inducing HBV-specific host immune responses. This review aimed to systematically synthesize updated evidence on the efficacy and safety of TVs in patients with CHB.
METHODS: This systematic review was performed by searching different databases from January to February 2021. Completed randomized controlled trials that reported TVs' efficacy and/or safety for treating CHB compared with the standard of care (SOC) or placebo were included. Efficacy and safety estimates were reported as the logarithm of the odds ratio and risk differences, respectively. I2 > 50% was considered significant heterogeneity. Significant publication bias was considered when Egger's test P value < .10. The risk of bias was assessed using the Cochrane Risk of Bias tool. The GRADE methodology was used to assess the certainty of the evidence for each outcome.
RESULTS: Twenty-four articles with 2889 pooled samples were included. TVs made a significant difference in hepatitis B envelope antigen (HBeAg) SC (log OR = 0.76, P = .01) and (log OR = 0.40, P = .03) compared to placebo and combination therapy, respectively. HBeAg SC was significantly affected by TVs at the end of follow up (log OR = 0.49, P = .01), with significant HBsAg mean difference (MD = -0.62, P = .00). At the end of treatment, the TVs had no significant effect on HBV DNA negativity over the SOC (log OR = 0.62, P = .09) or placebo (log OR = -0.07, P = .91). TVs do not significantly affect the risk of serious adverse events (RD 0.02, 95% CI 0.00-0.04).
CONCLUSION: In patients with CHB, TVs had significant effects on HBeAg SC compared to the SOC or placebo. There was no significant difference between serious adverse events. TVs are promising treatment strategy to overcome CHB.
<P>PROBLEM TO BE SOLVED: To provide a method for modulating an immune response in a subject.  <P>SOLUTION: The method and a composition for modulating the immune response in the subject are provided. The method includes administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor (e.g. protein A (PA)) sufficient to modulate the immune response. The composition includes the lymphocyte differentiation factor (e.g. protein A (PA)) in an amount of less than 1 μg. In addition, the method relieves inflammatory response in a subject with inflammatory response or a subject with a risk of inflammatory response. The method includes administering to the subject the composition comprising an effective amount of protein A (PA) sufficient to relieve the immune response.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
A Nature Medicine paper published in January 2024 describes eight cases of iatrogenic Alzheimer's disease in individuals who received cadaveric pituitary-derived human growth hormone. The paper's conclusions argue for the transmissibility of Alzheimer's disease, which, if true, would create a significant public health crisis. For example, neurosurgical practices would require substantial revision, and many individuals who have undergone neurosurgical procedures would now be at considerable risk of Alzheimer's disease. A detailed review of the presented cases reveals that they do not have Alzheimer's disease, and there are alternative explanations for the cognitive decline described. In people with progressive cognitive decline, the diagnosis of Alzheimer's disease requires a demonstration of amyloid and tau pathology or amyloid and tau biomarkers. Extensive tau pathology is not demonstrated, and some also lack amyloid beta pathology. The cases described in this paper do not meet the criteria for dementia due to Alzheimer's disease by clinical and pathological standards. HIGHLIGHTS: Creutzfeldt-Jakob disease has been transmitted by cadaveric growth hormone. There is no evidence for the transmission of Alzheimer's disease by cadaveric growth hormone. There is no evidence that Alzheimer's disease is transmissible.
Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.
PROBLEM TO BE SOLVED: To obtain a makeup cosmetic, excellent in adhesion and durability and pharmaceutically satisfactory by making the cosmetic include a highly viscous lubricant and particles treated with a perfluoroalkyl. SOLUTION: This cosmetic contains (A) a highly viscous lubricant and (B) particles treated with a perfluoroalkyl. The component A is preferably liquid or viscous fluid having a viscosity of 500 cSt. or more, and preferably an ester and/or highly viscous silicone, the ester being produced, e.g. by reacting a 12-30C branched fatty acid and/or unsaturated fatty acid, which may have hydroxyl group, with propylene glycol, glycerin, or a 12-30C branched or unsaturated higher alcohol. The cosmetic contains the component A preferably at 0.1 to 10 wt.%, and component B at 0.1 to 50 wt.%. It is preferably used for makeup purposes.
PURPOSE:To develop soft capsules contg. self-emulsifiable and dispersible type carotenoids having high stability and a wide range of uses by dissolving or suspending carotenoids into a system consisting of a fat or oil, surfactant and of polyhydric alcohol then forming the same into soft capsules. CONSTITUTION:Soft capsule agents which contain in high concn. carotenoids insolube in water and poorly stable and contain self-emulsifiable and dispersible type carotenoids usable in a highly stable state over a wide range are prepd. Such capsules are prepd. by dissolving or suspending carotenoids such as alpha, beta, gamma-carotenes, xanthophyll, lycopene, canthaxantine, or the like into a system consisting of animal or vegetable fat or oil, surfactant such as hydrophilic glycerol, fatty acid ester or the like of 0.02-1 based on of one fat or oil and >6 HLB, contg. also polyhydric alochols such as glycerol, propylene glycol or the like of likewise 0.02-1 based on one fat or oil, then forming the mixture into soft capsules.
Chimeric antigen receptor T cell (CAR T) therapy has reached a milestone in eradication of B cell malignancies, but no beneficial effect on solid tumors has been achieved. A porous microneedle patch is disclosed that can carry CAR T cells to a solid tumor (or other cell type). The device is a cellular porous microneedle patch that can contain CAR T cells and allow for seeding of the CAR T cells with an in situ osmotic medium after surgical resection of the solid tumor. CAR T cells loaded in microtip-end wells are easily shed to the tumor in a uniformly dispersed manner without losing their activity. This microneedle-mediated local delivery enhances infiltration and immune stimulation of CAR T cells compared to direct intratumoral injection. Such customizable patches provide a transformation platform for the decentralized inoculation of living cells for the treatment of a variety of diseases. Other cell types may be loaded into the porous microneedles.
Administer cycle 1 with Fludarabine and Cyclophosphamide (FC) alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
BACKGROUND: As chronic kidney disease (CKD) progresses, metabolites undergo diverse transformations. Nevertheless, the impact of these metabolic changes on the etiology, progression, and prognosis of CKD remains uncertain. Our objective is to conduct a metabolomics analysis to scrutinize metabolites and identify significant metabolic pathways implicated in CKD progression, thereby pinpointing potential therapeutic targets for CKD management.
METHODS: We recruited 145 patients with CKD and determined their mGFR by measuring the plasma iohexol clearance, whereupon we partitioned them into four groups based on their mGFR values. Non-targeted metabolomics analysis was conducted using UPLC-MS/MS assays. Differential metabolites were identified via one-way ANOVA, PCA, PLS-DA, and OPLS-DA analyses employing the MetaboAnalyst 5.0 platform. Ultimately, we performed differential metabolite pathway enrichment analysis, using both the MetaboAnalyst 5.0 platform and the MBRole2.0 database.
RESULTS: According to the findings of the MBRole2.0 and MetaboAnalyst 5.0 enrichment analysis, six amino acid metabolism pathways were discovered to have significant roles in the progression of CKD, with the glycine, serine, and threonine metabolism pathway being the most prominent. The latter enriched 14 differential metabolites, of which six decreased while two increased concomitantly with renal function deterioration.
CONCLUSIONS: The metabolic analysis unveiled that glycine, serine, and threonine metabolism plays a pivotal role in the progression of CKD. Specifically, glycine was found to increase while serine decreased with the deterioration of CKD.